The firm increased its price target by $1 to $70 on shares of the pharmacy benefit manager.
"We are now increasingly confident that ESI will serve and monetize the Anthem (ANTM) contract through 2019, and that the two companies may even find their way to a resolution," Deutsche Bank said.
Consensus estimates for 2017 appear low, as improved retention and profit growth per prescription should lead to mid single-digit operating profit and low double-digit earnings per share growth, the firm added.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B-.
Express Scripts' strengths such as its impressive record of earnings per share growth, revenue growth, notable return on equity, good cash flow from operations and increase in net income outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
You can view the full analysis from the report here: ESRX
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.